US PAD Prevalence
8–12 M
An estimated 8–12 million Americans have PAD; approximately 200,000 develop critical limb-threatening ischemia (CLTI) annually — the end-stage manifestation that defines the hospice population.[1]
What Is It
Definition, mechanism, and the clinical reality of end-stage peripheral arterial disease at end of life. What the hospice team needs to understand on day one.
Cardiovascular Death Risk
3–5×
PAD patients have 3–5× higher cardiovascular mortality than age-matched controls. The disease in the legs is the same disease killing the heart and brain.[2]
Amputation Rate — CLTI Without Revasc
25–40%
Major amputation at 1 year without revascularization reaches 25–40%. The choice between intervention and amputation defines the clinical decision architecture.[3]
Diabetes-PAD Amplification
2× Risk
Diabetes doubles PAD risk and dramatically accelerates wound complications. The combination of PAD and diabetic neuropathy accounts for the majority of non-traumatic lower limb amputations in the US.[4]
Peripheral arterial disease is the manifestation of systemic atherosclerosis in the vessels supplying the legs. Plaque accumulation narrows the iliac, femoral, popliteal, and tibial arteries progressively — first causing claudication (exertional leg pain that resolves with rest), then rest pain (pain at night and at rest when gravity-assisted perfusion is lost), then tissue loss (ulceration and gangrene). The transition from claudication to rest pain marks the transition from PAD to critical limb-threatening ischemia — a sentinel clinical event that demands urgent vascular assessment and that defines the population most likely to arrive in hospice care.[1]
End-stage PAD in the hospice context is defined by the exhaustion of revascularization options, the establishment of ischemic rest pain as a dominant and severe symptom, the presence of ischemic ulceration or gangrene, and the clinical reality that the wound on the foot is a window into a systemic vascular failure that has already affected the coronary and carotid circulation. These patients carry simultaneous cardiovascular risk at levels equivalent to patients with established coronary artery disease — stroke, myocardial infarction, and sudden cardiac death are concurrent threats alongside the limb-specific disease.[2]
The pain of ischemic rest pain is among the most severe and most undertreated pain syndromes in all of hospice medicine. It is constant, burning, and aching. It wakes patients from sleep. It forces them to hang the affected leg over the side of the bed at 3 AM to allow gravity to assist perfusion. It drives some patients to request amputation solely for pain relief. It requires aggressive multimodal analgesia from day one of hospice enrollment — not after a trial of acetaminophen, not PRN, not after the patient asks for something stronger. From the first visit.[5]
🧭 Clinical framing
Peripheral arterial disease is not a leg disease. It is a systemic atherosclerotic disease that announces itself through the legs. The patient with critical limb-threatening ischemia has the same pathological process occluding the coronary arteries and carotid arteries that is occluding the femoral and tibial arteries. Every PAD patient on your hospice census is simultaneously a cardiac patient and a cerebrovascular patient — and should be managed with that systemic perspective. The wound on the foot is not the disease. It is the visible manifestation of a body-wide vascular failure. Manage the symptom burden accordingly: pain is the dominant clinical problem, systemic cardiovascular events are the dominant mortality risk, and the grief of limb loss and disfigurement is the dominant psychosocial challenge.
"When you walk into the room and the patient is sitting in a recliner at 2 PM with the foot hanging over the edge and an empty bed behind them — that's your diagnosis. That patient has ischemic rest pain that nobody has adequately treated. The recliner is the clinical sign. The dangling foot is the treatment they've invented for themselves because we haven't done our job yet. Fix it today."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, classification systems, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it and understand what it means for comfort care.
Non-Invasive Vascular Assessment
- Ankle-Brachial Index (ABI): Foundational diagnostic tool. ABI = ankle systolic pressure ÷ brachial systolic pressure. Normal 1.0–1.4; borderline 0.9–1.0; mild PAD 0.7–0.89; moderate PAD 0.4–0.69; severe PAD <0.4. CLTI defined as rest pain with ABI <0.4 or toe pressure <30 mmHg or TcPO₂ <20 mmHg. Falsely elevated in diabetes and renal disease from arterial calcification.[6]
- Toe-Brachial Index (TBI): More reliable than ABI in calcified arteries (diabetes, ESRD). TBI <0.70 = PAD; TBI <0.15 = critical ischemia. Preferred in the diabetic population where ABI is unreliable.[6]
- Transcutaneous Oxygen Pressure (TcPO₂): Measures skin oxygen delivery directly. TcPO₂ <20 mmHg = critical ischemia and poor wound healing potential; <10 mmHg = amputation-level ischemia. Predicts wound healing and guides amputation level decisions.[7]
- Duplex Ultrasound: Non-invasive vascular imaging defining stenosis location, severity, and flow velocities across the aortoiliac, femoral, popliteal, and tibial segments. Used for revascularization planning and post-procedure surveillance.[8]
Advanced Imaging & Angiography
- CT Angiography (CTA): Detailed anatomical roadmap of aortoiliac and peripheral arterial disease. Defines run-off vessels for bypass planning. Contrast nephropathy risk in renal impairment — important pre-revascularization consideration.[8]
- MR Angiography (MRA): Excellent soft tissue detail. No radiation. Gadolinium risk in severe renal failure (nephrogenic systemic fibrosis). Excellent for bypass planning in tibial vessels where calcification obscures CTA.[8]
- Conventional Angiography: Catheter-based gold standard for procedural planning. Simultaneous diagnostic and therapeutic intervention possible. Contrast and access site risks apply.[9]
Wound & Disease Classification Systems
- Wagner Classification: Grade 0 — no open lesion; Grade 1 — superficial ulcer; Grade 2 — deep ulcer to tendon/capsule/bone; Grade 3 — deep ulcer with abscess or osteomyelitis; Grade 4 — forefoot gangrene; Grade 5 — whole foot gangrene.[10]
- WIfI Classification (Wound, Ischemia, foot Infection): Preferred for CLTI risk stratification. Integrates wound depth, ischemia severity, and infection severity into a composite risk score predicting amputation risk and revascularization benefit. Now the standard for vascular surgery decision-making.[11]
- Rutherford Classification: Categories 4–6 define CLTI: 4 = ischemic rest pain; 5 = minor tissue loss (non-healing ulcer, focal gangrene with diffuse pedal ischemia); 6 = major tissue loss (extending above transmetatarsal level, functional foot no longer salvageable). Rutherford 5–6 are the hospice population.[9]
What to Look for in Hospice Records
- Vascular surgery evaluation: Was the patient formally evaluated for revascularization at a high-volume center? If not, ask why. Some patients are enrolled without adequate vascular assessment.
- Prior revascularization history: Number and type of prior procedures (PTA, stents, bypass), graft type, and failure pattern. Failed bypass with no further targets defines the no-option patient.
- ABI/TBI/TcPO₂ values: These numbers tell you perfusion status and wound healing potential. ABI <0.4 and TcPO₂ <20 mmHg confirm critical ischemia.
- Wound status and classification: Wagner grade, WIfI score, wound dimensions and depth, presence of exposed bone or tendon, infection status, and gangrene type (dry vs. wet).
- Comorbidity burden: Diabetes, CKD/ESRD on dialysis, coronary artery disease, prior stroke — these define the systemic disease severity and overall prognosis.
💡 For families
Your loved one's vascular disease has already been diagnosed and evaluated by specialists. In hospice, we do not repeat these tests — the focus is entirely on comfort. The numbers in the medical record tell us how severe the blood flow problem is and help us plan the best pain management and wound care approach. If you have questions about the diagnosis or prior treatments, your hospice team can explain what was tried and why the focus has shifted to comfort.
Causes & Risk Factors
Modifiable, hereditary, and systemic risk factors. Relevant for family conversations, addressing guilt, and answering "why did this happen?"
Modifiable Risk Factors
- Tobacco smoking (2–4× risk): The most potent modifiable risk factor. Smoking causes endothelial injury, promotes plaque formation, impairs peripheral vasodilation, and dramatically accelerates disease progression. PAD is one of the most tobacco-sensitive vascular diseases. Cessation slows progression but does not reverse established disease. Ask about lifetime pack-year history.[12]
- Diabetes mellitus (2× risk): Doubles PAD risk and profoundly accelerates progression to CLTI. Diabetic patients develop PAD at a younger age, in more distal tibial and pedal vessels, with more extensive calcification. Diabetic neuropathy removes protective pain sensation, allowing wounds to develop and progress undetected. Approximately 60% of non-traumatic amputations occur in diabetic patients.[4]
- Hypertension: Chronic pressure overload damages the arterial wall and accelerates atherosclerosis. Independent risk factor for PAD progression.[13]
- Hyperlipidemia: LDL-driven plaque formation is the central mechanism of atherosclerosis. Statin therapy reduces PAD progression and cardiovascular events. High lipoprotein(a) is an underrecognized independent PAD risk factor.[14]
Non-Modifiable & Systemic Factors
- Chronic kidney disease / ESRD: Dialysis patients have the highest PAD risk and worst CLTI outcomes. Arterial calcification from calcium-phosphate deposition, uremic vascular toxicity, and inflammatory activation create rapidly progressive disease. ESRD on dialysis with CLTI has 1-year mortality >40%.[15]
- Hyperhomocysteinemia: Promotes thrombosis and endothelial injury. B-vitamin supplementation may help if homocysteine is elevated.[13]
- Inflammatory conditions: Rheumatoid arthritis, lupus, vasculitis — Takayasu arteritis, thromboangiitis obliterans (Buerger's disease) in young smokers. Inflammatory-driven accelerated atherosclerosis.[16]
- Prior pelvic/groin radiation: Radiation-induced accelerated atherosclerosis with 10–20 year latency. Iliac and femoral stenosis in cancer survivors — a growing population.[16]
- Race/ethnicity disparities: Black patients have 2–3× higher PAD prevalence than white patients and are amputated at significantly higher rates — even after controlling for disease severity and comorbidities. This disparity reflects unequal access to vascular specialists, revascularization, and limb salvage programs — not biological predisposition. Hispanic patients also face elevated PAD risk with similar access barriers.[17]
❤️ For families: "Why did this happen?"
Peripheral arterial disease is caused by a buildup of cholesterol and calcium in the arteries — the same process that causes heart attacks and strokes. Risk factors include smoking, diabetes, high blood pressure, and high cholesterol — but many people with PAD had multiple risk factors working together over decades. This was not caused by something your loved one did wrong. It is a disease, and it was building for a long time before anyone knew it was there. If your loved one smoked, know that smoking is an addiction — not a moral failure. The guilt many patients carry about their smoking history is real and deserves compassion, not judgment.
⚕ Clinician note: Racial disparities in PAD outcomes
Black Americans are amputated at rates 2–4× higher than white Americans, even after controlling for disease severity, insurance status, and comorbidities. This is not a biological difference — it is a systemic access failure. Black patients are less likely to be referred to vascular surgery, less likely to receive revascularization, and more likely to present with advanced CLTI. At hospice enrollment, ask: was this patient evaluated by a vascular specialist at a high-volume center? If not, understand the structural reasons why. Your awareness of this disparity is part of equitable care.[17]
Treatments & Procedures
What disease-directed treatments this patient may have received. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
Medical therapy for PAD includes antiplatelet therapy (aspirin 81–325 mg daily or clopidogrel 75 mg daily — reduces cardiovascular events per CAPRIE and CHARISMA trials), statin therapy (reduces cardiovascular events and may slow PAD progression; reassess in purely comfort-focused goals — no immediate comfort benefit), ACE inhibitor or ARB (HOPE trial — ramipril reduces cardiovascular events in PAD; reassess in frail patients with hypotension), cilostazol (PDE3 inhibitor — improves claudication walking distance; contraindicated in heart failure; in CLTI, claudication is not the clinical problem and cilostazol has no benefit), and supervised exercise therapy (claudication treatment with significant evidence for improving walking distance and quality of life; not applicable in CLTI with rest pain or ulceration).[14]
Revascularization Procedures
- Endovascular revascularization: Percutaneous transluminal angioplasty (balloon dilation), drug-coated balloon (reduces restenosis), stenting (bare metal or drug-eluting), atherectomy (rotational, directional, orbital — removes plaque), subintimal angioplasty for total occlusions. Most appropriate for iliac and femoropopliteal disease. Tibial vessel angioplasty for CLTI increasingly performed with small-vessel techniques and retrograde pedal access for complex tibial occlusions.[9]
- Surgical revascularization: Aortobifemoral bypass (gold standard for aortoiliac occlusive disease), femoral-popliteal bypass (above-knee or below-knee), femoral-tibial bypass (using reversed saphenous vein), in-situ bypass, infrapopliteal bypass for CLTI with tibial targets, endarterectomy for focal disease.[9]
- Hybrid procedures: Combined endovascular and surgical approaches in the same session for multi-level disease.[9]
Amputation & Wound Care
- Amputation levels: Toe amputation (single or multiple), transmetatarsal amputation (TMA), below-knee amputation (BKA), above-knee amputation (AKA). Level determined by perfusion adequacy at the proposed level. BKA preserves the knee joint — critical for mobility and prosthetic use. AKA has faster primary healing but significantly worse functional outcomes. Major amputation perioperative mortality: 5–10% at 30 days; 1-year mortality post-major amputation: 30–50%.[18]
- Wound care in CLTI: Ongoing management regardless of revascularization status. In the comfort context, wound care goals shift from healing to comfort — pain management during dressing changes, odor control (metronidazole gel), infection prevention, protection of dry gangrene from trauma. Debridement decisions depend on goals: autolytic debridement (gentle, moisture-retentive) preferred over sharp surgical debridement in comfort-focused patients.[19]
- Deprescribing at hospice enrollment: Reassess antiplatelets (bleeding risk vs. cardiovascular benefit in frail patients), statins (no immediate comfort benefit), ACE inhibitors (hypotension risk), cilostazol (no CLTI benefit). Maintain medications that serve comfort: opioids, gabapentin, antihypertensives for symptom management.[20]
When Therapy Makes Sense
Evidence-based criteria for pursuing disease-directed intervention in CLTI. This is not about giving up or holding on — it's about reading the vascular data correctly.
The Global Vascular Guidelines (GVG 2019) and Society for Vascular Surgery practice guidelines define evidence-based criteria for revascularization in CLTI. Even in hospice, some patients benefit from vascular interventions that serve comfort goals — reducing pain, controlling infection, avoiding unnecessary major amputation. The key is matching the intervention to the patient's goals and physiological reserve.[3]
- 01Urgent vascular surgery consultation if CLTI has not been formally evaluated for revascularization: If a patient is enrolled on hospice with CLTI and there is no record of vascular surgery evaluation, ask why. Some patients are enrolled without adequate vascular assessment. A second opinion at a comprehensive vascular center before accepting no-option status is appropriate and worth pursuing — even in the hospice context.[3]
- 02Endovascular revascularization in ECOG 0–2 with identifiable tibial or pedal target: Even in frail patients, minimally invasive endovascular revascularization can be performed under local anesthesia with sedation. Successful revascularization reduces pain, promotes wound healing, and may avoid major amputation. The risk-benefit discussion belongs at enrollment.[9]
- 03Minor amputation (toe or TMA) with adequate healing potential: Localized gangrene with adequate proximal perfusion (ABI >0.5 or TBI >0.15) — minor amputation can eliminate the source of infection and pain. In dry gangrene without infection, autoamputation (natural demarcation) may be the comfort approach. In wet gangrene with sepsis, urgent surgery is a comfort discussion.[18]
- 04Wound care optimization: Regardless of revascularization status, wound care in CLTI can meaningfully reduce pain, odor, and infection risk. This is a comfort intervention at every stage — not a disease-directed therapy. Comfort-focused wound care belongs in every PAD hospice plan of care.[19]
- 05Aggressive opioid management for ischemic rest pain: This is the most undertreated severe pain in hospice. Morphine or oxycodone around the clock from day one. Assess pain at every visit with the same precision as a cancer pain assessment. Do not wait for the patient to ask.[5]
- 06Patient goals explicitly include pain management and wound control with full understanding of prognosis: A well-informed patient who understands the disease trajectory and chooses targeted intervention for comfort purposes — pain reduction, odor control, infection prevention — should receive it without arbitrary categorical barriers.
When It Doesn't
Knowing when intervention stops helping is not clinical failure. It is the most important clinical skill in end-stage vascular disease.
Patients with CLTI are among the most under-referred to palliative care in all of vascular medicine. Many patients undergo repeated revascularization attempts, multiple hospitalizations, and progressive tissue loss before anyone discusses comfort-focused goals. The transition to hospice-appropriate care is often delayed until the patient is septic, post-amputation, or actively dying — all of which reduce the window for meaningful comfort management.[20]
- 01No revascularization targets identified by experienced vascular surgeon at high-volume center: Diffuse distal tibial and pedal vessel occlusion without patent outflow target. Failed prior bypass and multiple prior endovascular procedures with no further anatomy for intervention. This defines the no-option CLTI patient.[3]
- 02ECOG ≥3: The patient who cannot tolerate even local anesthesia for endovascular intervention. Prohibitive cardiac risk for any operative procedure. The physiological reserve does not support intervention — the risk of the procedure exceeds any potential benefit.[18]
- 03Patient has made informed autonomous decision to decline further intervention: The patient who understands that without intervention the limb will progress to gangrene and may require amputation, and who chooses comfort over intervention, has made a fully autonomous decision that must be honored completely. This is not giving up. This is clarity.[20]
- 04Estimated survival <6 months from systemic cardiovascular disease burden: When the overall prognosis is limited by concurrent coronary artery disease, prior stroke, ESRD, or severe cardiac failure, aggressive limb-directed intervention no longer serves quality of life. Hospice enrollment is appropriate.
- 05Patient goals shift explicitly to pain control, wound comfort, and home death: When a fully informed patient prioritizes comfort at home over hospitalization for intervention, that decision is not clinical failure. It is the clearest expression of patient-centered care.
📋 Dry vs. Wet Gangrene — The Most Important Clinical Distinction
Dry gangrene: The tissue is mummified, dark, and demarcating. There is no active infection and no systemic sepsis. The correct management in a comfort-focused patient is conservative — protect from trauma, keep dry, monitor for any transition to wet gangrene at every visit. Allow natural demarcation to proceed. This is watchful comfort management, not abandonment. Dry gangrene is not a clinical emergency.[21]
Wet gangrene: The tissue is infected, moist, malodorous (putrid or feculent odor), with erythema extending into viable tissue, warmth, and possible fever or systemic signs of sepsis. This IS a clinical emergency even in the comfort-focused patient. Wet gangrene requires: comfort-directed antibiotics immediately (oral or IV depending on severity), wound culture, consideration of urgent surgical consultation if patient goals allow, and reassessment of goals if sepsis progresses. A patient who has chosen comfort-focused care still deserves aggressive management of the agony of sepsis — this is a comfort intervention, not a disease-directed one.[21]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches for end-stage PAD. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Aggressive Opioid Titration for Ischemic Rest Pain — Day One Priority
Grade AMorphine IR 5–10 mg PO q4h ATC + equivalent PRN; or Oxycodone IR 5–10 mg PO q4h ATC; convert to long-acting when daily requirement established
Ischemic rest pain is a constant, severe, burning, and aching pain that wakes patients from sleep, forces them to hang the leg dependently over the side of the bed for gravity-assisted perfusion, and drives some patients to request amputation solely for pain relief. This pain is not undertreated by hospice convention — it is undertreated because ischemic rest pain as a primary indication for around-the-clock opioids is systematically under-recognized. Morphine or oxycodone ATC from the first hospice visit, with generous PRN dosing. Multimodal analgesia with gabapentin for the neuropathic burning component. A pain score of 8/10 at enrollment should never be accepted as expected. This is the most important comfort intervention in end-stage PAD.[5]
Dependent Positioning for Ischemic Rest Pain Relief
Grade BLeg dependent or flat — never elevated; recliner with foot below heart; foam footboard or bed extender for dependent positioning in bed
Ischemic rest pain increases when the leg is elevated because gravity-assisted arterial perfusion is reduced. The patient instinctively hangs the leg over the side of the bed or sleeps in a recliner — this is correct physiological behavior. Support the patient in dependent positioning. Do not attempt to elevate the legs for "edema" in a CLTI patient — elevation worsens ischemia. The edema from dependent positioning is venous and secondary and is far less important than maintaining perfusion. A foam footboard or bed extender that allows the foot to hang comfortably is a meaningful comfort intervention.[22]
Dry Gangrene Autoamputation — Conservative Management
Grade BDaily gentle cleansing with normal saline; non-adherent protective dressing; keep dry; monitor daily for transition to wet gangrene
Dry gangrene without systemic infection will naturally demarcate and self-amputate over weeks to months. Conservative management with daily gentle cleansing, protective dressings, and monitoring for transition to wet gangrene is appropriate comfort care. This approach avoids surgical procedures in patients who are not surgical candidates or who decline surgery. The clinical task is vigilant monitoring for the transition from dry to wet gangrene — that transition changes everything and requires same-day nursing assessment. Family education: a dry, dark, mummified toe that is separating naturally is not an emergency. A toe that becomes wet, red, swollen, or foul-smelling IS an emergency.[21]
Spinal Cord Stimulation (SCS) for Refractory Ischemic Pain
Grade BPercutaneous epidural lead placement; trial period followed by permanent implant if ≥50% pain reduction
SCS has RCT evidence for improving pain control and limb salvage in non-reconstructable CLTI. The SCS-CLTI randomized trial demonstrated significant pain reduction and reduced amputation rates. Appropriate for patients with refractory ischemic pain not controlled by maximal medical therapy, who have life expectancy sufficient to benefit from implantation, and who are not surgical candidates for revascularization. Requires specialized pain medicine or neurosurgical referral. In hospice, generally appropriate only for patients with expected survival of months — not days or weeks.[23]
Ketamine for Refractory Ischemic Neuropathic Pain
Grade CBurst ketamine 0.1–0.3 mg/kg/hr IV/SQ over 4–24 hours; or low-dose oral ketamine 10–25 mg PO TID
NMDA receptor antagonism addresses central sensitization that develops in chronic ischemic pain. Particularly useful in patients with opioid tolerance and escalating pain requirements. Limited but growing evidence in palliative care settings for neuropathic and ischemic pain syndromes. Monitor for dissociative symptoms, hallucinations. Inpatient or continuous care setting recommended for IV administration. Oral ketamine for outpatient use as adjunct to opioid regimen.[24]
Hyperbaric Oxygen Therapy (HBOT)
Grade C1.5–2.4 ATA for 60–90 min; 20–40 sessions; requires TcPO₂ response testing
HBOT increases tissue oxygenation and may promote wound healing in selected CLTI patients. Evidence is mixed — most benefit seen in diabetic foot ulcers with marginal perfusion (TcPO₂ 20–40 mmHg range). In patients with TcPO₂ <10 mmHg, benefit is minimal because there is insufficient vascular infrastructure to deliver the oxygen. Logistically demanding for debilitated patients. Generally not appropriate for comfort-focused hospice patients, but may be considered in patients on concurrent palliative and disease-directed care with marginal but present perfusion.[25]
Music Therapy for Pain and Anxiety
Grade B30–60 min sessions; patient-selected music; certified music therapist preferred; can be implemented with personal devices
Multiple meta-analyses demonstrate music therapy reduces pain perception, anxiety, and opioid requirements in chronic pain populations. Particularly valuable during wound care procedures and dressing changes, which are among the most painful and anxiety-provoking experiences for CLTI patients. No contraindications. Can be implemented immediately at no cost with patient-selected music on personal devices. Complementary to pharmacological management — does not replace opioids but may reduce breakthrough requirements.[26]
TENS for Ischemic and Phantom Limb Pain
Grade CHigh-frequency TENS (50–100 Hz); 30–60 min sessions; electrode placement proximal to ischemic area (avoid placing on ischemic skin); for phantom limb: contralateral limb or residual limb proximal to amputation
Transcutaneous electrical nerve stimulation may provide adjunctive analgesia for ischemic rest pain and phantom limb pain. Place electrodes proximal to the ischemic area — not directly on ischemic or gangrenous tissue. For phantom limb pain, mirror therapy combined with TENS may enhance benefit. Limited evidence in CLTI specifically, but established safety profile and low cost make it a reasonable adjunct. Do not place electrodes on infected wounds or across the chest in patients with cardiac devices.[27]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to end-stage PAD. Patients will use supplements — this section helps you have the right conversation.
⚠ Critical Warning: End-Stage PAD and Supplement Safety
End-stage PAD creates a uniquely dangerous supplement environment. Antiplatelet therapy with aspirin or clopidogrel is standard — any supplement with additional antiplatelet activity compounds bleeding risk in patients with ischemic wounds that may not hemostase normally due to poor perfusion. Wound infection is a constant threat — any supplement that further compromises immune function is dangerous. And the ischemic wound itself impairs absorption of many oral supplements. The default in end-stage PAD should be: verify every supplement against current antiplatelet or anticoagulant therapy, and avoid any supplement that impairs wound healing, promotes vasoconstriction, or compounds antiplatelet effects.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your blood thinners and pain medications, and in PAD, bleeding from a wound that can't clot properly is a real risk.' Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger (low dose) | Grade B | 500 mg/day maximum | Nausea from opioids and systemic disease; mild anti-inflammatory; may improve GI motility impaired by opioids | Antiplatelet effect becomes significant at higher doses in patients already on aspirin or clopidogrel — limit strictly to 500 mg/day. Safe at this dose on single antiplatelet therapy. Avoid in patients on dual antiplatelet therapy or anticoagulation.[28] |
| Vitamin C (food-source) | Grade C | 200–500 mg daily | Wound healing support; collagen synthesis requires ascorbate; malnutrition and vitamin C deficiency impair wound healing in CLTI patients with nutritional deficiency and cachexia | No antiplatelet risk at food-source doses (200–500 mg). Does not compound bleeding risk. Relevant in cachectic PAD patients with documented or likely nutritional deficiency. Megadoses (>1000 mg) may cause GI upset and oxalate nephropathy in CKD patients.[29] |
| Zinc (food-source) | Grade C | 10–15 mg daily | Zinc deficiency impairs wound healing and immune function; supplementation at food-source levels supports tissue repair in malnourished CLTI patients | Avoid high-dose supplemental zinc (>40 mg/day) — competes with copper absorption and may paradoxically impair immune function. Food-source zinc from meat and legumes is appropriate. Monitor for metallic taste and nausea.[29] |
| Melatonin | Grade C | 1–3 mg at bedtime | Sleep disruption from ischemic rest pain is a primary quality-of-life problem; patients sleep in chairs or with legs dependent; melatonin as adjunct to pain management for circadian rhythm support | Minimal drug interactions. No antiplatelet effect. No wound healing impairment. Safe as adjunct sleep support alongside opioid pain management. Does not replace adequate analgesia — if pain is the cause of insomnia, treat the pain first.[30] |
🚫 Avoid in End-Stage PAD
- Ginkgo biloba: Potent antiplatelet — inhibits platelet-activating factor. Compounds bleeding risk with aspirin or clopidogrel in patients whose ischemic wounds already have impaired hemostasis. Case reports of hemorrhagic complications in PAD patients on concurrent antiplatelet therapy. Do not use.[31]
- Garlic supplements (high-dose): Allicin has significant antiplatelet and antithrombotic activity at supplement doses. Compounds bleeding risk from ischemic wounds. Culinary garlic at normal cooking amounts is not a concern — concentrated supplements are.[31]
- Vitamin E (high-dose >400 IU): Anticoagulant and antiplatelet at high doses. Meta-analyses suggest increased all-cause mortality at doses >400 IU. Compounds bleeding risk. No documented wound healing benefit at any dose in CLTI.[31]
- St. John's Wort: Potent CYP3A4 inducer — reduces effectiveness of opioids (especially methadone, fentanyl), clopidogrel activation (paradoxically complex interaction), and multiple other medications. In a PAD patient on opioids and antiplatelets, St. John's Wort creates unpredictable drug levels. Do not use.[31]
- Dong Quai: Contains coumarins with anticoagulant activity. Compounds bleeding risk in patients on antiplatelets. Photosensitivity risk in patients with ischemic skin changes.[31]
- Ephedra (Ma Huang): Potent vasoconstrictor — directly worsens peripheral ischemia. Contraindicated absolutely in any patient with PAD. Increases blood pressure, heart rate, and cardiac risk in a population already at extreme cardiovascular risk. Banned by FDA but still available through some sources.[31]
Timeline Guide
A guide, not a prediction. PAD progression is shaped by revascularization access, diabetes status, renal function, and the systemic atherosclerotic burden.
PAD follows a progressive spectrum from claudication to critical limb-threatening ischemia to tissue loss and death. The pace varies enormously: a patient with well-managed risk factors and access to revascularization may remain in the claudication phase for years. A diabetic patient on dialysis with no revascularization options may progress from first rest pain to death in weeks to months. Comorbid cardiac disease, CKD, and diabetes are the major accelerators. Use this timeline to guide conversations — but every patient writes their own version.[1]
YRS–
MOS
MOS
Claudication Phase — PAD Diagnosed
- PAD diagnosed; lifestyle modification, smoking cessation, supervised exercise therapy initiated
- Ankle-brachial index documented; on antiplatelet therapy and statin
- Able to walk but limited by calf pain at consistent distances; cardiovascular risk management is the primary clinical task
- This phase can last years with optimal medical management
- Palliative care integration is rarely needed, but advance care planning around what the patient would want if they develop rest pain or require amputation is appropriate at this stage — the patient who has this conversation in the claudication phase is not ambushed by it in the CLTI phase
MOS–
1 YR
1 YR
Transition to Rest Pain & Tissue Loss
- ABI declining below 0.4; toe pressure below 30 mmHg; ischemic ulceration or tissue loss developing
- First episode of rest pain waking patient at night; patient instinctively hanging foot over edge of bed
- Urgent vascular surgery evaluation — CLTI is a vascular emergency; revascularization within days to weeks improves limb salvage
- If revascularization is possible, this is the window for intervention; if not, hospice integration should begin here alongside wound care
- The pain management conversation belongs now, not at end of life — start multimodal analgesia at first rest pain episode
WKS–
MOS
MOS
CLTI With Failed or Exhausted Revascularization
- Rest pain constant and severe; wound not healing despite wound care; gangrene present or developing
- Multiple hospitalizations for wound infection or revascularization attempts; ECOG declining
- Hospice enrollment most appropriate at this transition — the around-the-clock opioid conversation must happen at enrollment
- Wound care goals explicitly established: comfort, odor control, infection prevention — not healing
- Family education about wound care, dependent positioning, pain management protocol, and wet vs. dry gangrene recognition begins now
- Phantom limb pain prophylaxis if amputation has occurred or is planned — gabapentin started preemptively
DAYS–
WKS
WKS
Active Dying With Ischemic Limb
- Rest pain requiring around-the-clock opioids with frequent breakthrough dosing; possible sepsis from wet gangrene requiring comfort-directed antibiotics
- Limb may be mottled, gangrenous, and malodorous — aggressive odor management with metronidazole gel and activated charcoal dressings
- Declining oral intake; conversion to subcutaneous opioid route; bed-bound or recliner-bound
- Family wound care education critical — dressing changes, odor management, when to call the nurse
- Goals-of-care reaffirmation if sepsis develops: comfort-directed antibiotics vs. aggressive antibiotic escalation vs. withdrawal of antibiotics
- Ensure comfort kit is complete: morphine SQ, midazolam SQ (for terminal agitation or refractory pain crisis), glycopyrrolate, lorazepam
HRS–
DAYS
DAYS
Final Hours
- Cheyne-Stokes or agonal breathing; mandibular breathing; mottling extending from ischemic limb centrally
- Unresponsive or minimally responsive; continue ATC opioids — ischemic pain persists in altered consciousness
- Terminal secretions — glycopyrrolate 0.2 mg SQ q4h; reposition gently; family education: "This sound is not distressing to your loved one"
- If sepsis crisis occurs: midazolam 2.5–5 mg SQ for agitation; morphine 2–5 mg SQ for pain and dyspnea; have medications pre-drawn and labeled at the bedside
- Family should be prepared: continue medications, provide presence, speak to the patient — auditory awareness may persist
Medications to Anticipate
Symptom-targeted pharmacology for end-stage PAD. What to have in the comfort kit, what to titrate first, and what the evidence supports.
🚨 Critical Note: Ischemic Rest Pain — The Most Undertreated Pain in Hospice
Ischemic rest pain is the most undertreated severe pain syndrome in hospice medicine. It is constant, burning, aching, and worsening when the leg is elevated. It wakes patients from sleep. It drives patients to hang their legs over the side of the bed at 3 AM. It causes some patients to request amputation solely for pain relief. It requires around-the-clock opioids from day one of hospice enrollment — not PRN, not waiting for the patient to ask, not after "trying Tylenol first." Assess ischemic rest pain as you would assess stage 4 cancer pain: with a numerical scale, with specific characterization of quality and timing, with explicit goals for pain control, and with a medication plan that achieves those goals. Accepting a pain score of 7/10 in a CLTI patient is a clinical failure. The goal is 3/10 or below. Titrate to achieve it.[5]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine or Oxycodone (ATC) | Opioid / Ischemic rest pain | Morphine IR 5–10 mg PO q4h ATC or Oxycodone IR 5–10 mg PO q4h ATC with equivalent PRN q1h breakthrough | Not PRN — continuous pain requires continuous coverage. Convert to long-acting formulation when daily oral requirement is established. SQ conversion when oral route fails: morphine 2.5–5 mg SQ q4h with PRN. A CLTI patient on acetaminophen alone at enrollment has never received adequate analgesia.[5] |
| Gabapentin or Pregabalin | Anticonvulsant / Neuropathic pain | Gabapentin 300 mg TID titrate to 900 mg TID; or Pregabalin 75 mg BID titrate to 150 mg BID | Essential for the neuropathic burning component of ischemic rest pain and ischemic neuropathy. Reduces neuropathic component and allows lower opioid doses. ⚠ Renally adjust — most CLTI patients have some degree of CKD. Also first-line for phantom limb pain prophylaxis.[32] |
| Dexamethasone | Corticosteroid / Peri-wound inflammation, appetite | 4–8 mg PO/SQ daily; taper after 5–7 days to lowest effective dose or discontinue | Reduces peri-wound inflammatory pain, improves appetite, general anti-inflammatory. Short course for acute flares. Monitor glucose in diabetic patients — most CLTI patients are diabetic. Taper to avoid adrenal suppression if used >2 weeks.[33] |
| Metronidazole gel (0.75%) | Topical antimicrobial / Wound odor | Apply to wound surface daily with dressing change | One of the most dignity-restoring interventions in PAD hospice. Anaerobic bacteria produce the characteristic putrid odor of gangrenous wounds. Topical metronidazole suppresses these bacteria without systemic exposure. Improvement within 3–5 days is dramatic. Order at first visit if any wound odor is present.[34] |
| Ketamine (low-dose) | NMDA antagonist / Refractory ischemic pain | Oral: 10–25 mg PO TID; IV/SQ burst: 0.1–0.3 mg/kg/hr over 4–24 hrs | For refractory ischemic pain with opioid tolerance and escalating requirements. Addresses central sensitization. Monitor for dissociative symptoms. Consider when opioid rotation and dose escalation are inadequate.[24] |
| Lidocaine 5% patches | Topical anesthetic / Localized pain | Apply to intact skin proximal to wound; 12 hours on / 12 hours off | Adjunctive for localized ischemic pain and phantom limb pain. Do not apply directly to open wounds or gangrenous tissue. Place on intact skin adjacent to the painful area. Useful for residual limb pain post-amputation.[27] |
| Ondansetron | 5-HT3 antagonist / Nausea | 4–8 mg PO/SQ q8h PRN | Opioid-induced nausea is common at initiation and dose escalation. Ondansetron safe alongside antiplatelets. Constipation as side effect — manage prophylactically with scheduled bowel regimen.[33] |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Anxiety from chronic severe pain, wound-related distress, and anticipatory grief. Adjunctive — not first-line for pain. Use with caution alongside opioids — additive CNS depression. Assess for underlying treatable cause: pain, existential distress, delirium.[33] |
| Midazolam | Benzodiazepine / Terminal agitation, refractory pain | 2.5–5 mg SQ PRN; CSCI 10–30 mg/24h for refractory agitation | Terminal agitation and catastrophic symptom management. Have in comfort kit pre-drawn and labeled at the bedside before crisis. For sepsis-related rigors and agitation in wet gangrene crisis. Document goals-of-care discussion before initiating continuous infusion.[33] |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h; or 0.6–1.2 mg/24h CSCI | Reduces terminal secretions without CNS effects. Preferred over hyoscine in conscious patients. Family education: "This medication reduces the fluid sound but will not eliminate it completely. The sound is not distressing to your loved one."[33] |
| Haloperidol | Antipsychotic / Delirium, nausea | 0.5–2 mg PO/SQ q6–8h | First-line for delirium in PAD patients — infection-related delirium common in wet gangrene and sepsis. Also effective for opioid-induced nausea (CTZ effect). Low anticholinergic burden. QTc monitoring ideal but not always practical in hospice setting.[33] |
| Doxepin (low-dose) | TCA / Insomnia, neuropathic pain | 10–25 mg PO QHS | Dual benefit: promotes sleep in patients with rest pain-related insomnia and provides mild neuropathic pain relief. H1 antagonism at low dose is the primary sedative mechanism. ⚠ Anticholinergic — use with caution in elderly, monitor for urinary retention.[33] |
| Megestrol acetate | Progestational / Cachexia, appetite | 400–800 mg PO daily | Appetite stimulant in cachectic PAD patients with poor nutritional intake. Modest evidence for weight gain. ⚠ DVT risk — significant in PAD patients with reduced mobility and venous stasis. Reassess risk-benefit in patients with prior VTE.[33] |
| Comfort-directed antibiotics | Antimicrobial / Wound infection, sepsis comfort | Based on wound culture; empiric: amoxicillin-clavulanate 875/125 mg PO BID; or metronidazole 500 mg PO TID for anaerobic coverage | In wet gangrene with sepsis: comfort-directed antibiotics prevent the agony of uncontrolled sepsis. This is a comfort intervention. Oral preferred; IV if oral not tolerated. Do not withhold antibiotics from a comfort-focused patient with wet gangrene — untreated sepsis causes suffering. Reassess goals if sepsis progresses despite antibiotics.[21] |
🌿 PAD Symptom Management Decision Tree
Evidence-based · Hospice-adapted · PAD-specificSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for End-Stage PAD
Morphine 20 mg/mL concentration SQ: For ischemic rest pain crisis and dyspnea — 2–5 mg SQ q1h PRN. Midazolam 5 mg/mL SQ: For terminal agitation, sepsis-related rigors, and refractory pain crisis — 2.5–5 mg SQ PRN. Glycopyrrolate 0.2 mg/mL SQ: For terminal secretions — 0.2 mg SQ q4h. Lorazepam 2 mg/mL SQ: For anxiety and adjunctive agitation — 0.5–1 mg SQ q4h PRN. Haloperidol 5 mg/mL SQ: For delirium and nausea — 0.5–2 mg SQ q6h. All medications must be pre-drawn and labeled at the bedside before the crisis — not during it. Families need to know which syringe is which and when to give what. Teach them before the emergency.
Clinician Pointers
High-yield clinical pearls for the hospice team managing end-stage PAD. The things not in the textbook — learned at the bedside over years of vascular hospice experience.
1
Ischemic rest pain demands around-the-clock opioids from the first visit
This pain is not PRN pain. It is constant, severe, and debilitating. The clinical error in PAD hospice is treating severe ischemic rest pain the same way as mild-moderate cancer pain that is responsive to acetaminophen and occasional opioid. Start morphine or oxycodone around the clock at enrollment. The patient who has been in pain for months has central sensitization that requires more aggressive initial management than acute pain. Do not wait for a pain diary. Treat the reported severity at the first visit. If the patient says 7/10, believe them and treat it now.[5]
2
Dry versus wet gangrene — assess at every visit
This is the most important clinical distinction in PAD hospice. Dry gangrene: mummified, dark, demarcating, no odor of infection, no fever, no systemic signs. Management: conservative, protective dressing, monitor for transition. Wet gangrene: moist, malodorous (putrid or feculent odor), erythema extending into viable tissue, warmth, possible fever, systemic signs. Management: urgent — comfort-directed antibiotics immediately, wound culture, consider surgical consultation if goals allow, reassess goals if sepsis progresses. The transition from dry to wet gangrene at any visit requires same-day nurse assessment and physician notification. Teach aides and families to recognize the difference.[21]
3
Do not elevate the ischemic leg — ever
The standard nursing instruction to "elevate the legs to reduce swelling" is directly harmful in CLTI. Elevation reduces gravity-assisted perfusion and worsens ischemia — potentially catastrophically. The edema in an ischemic limb is secondary to venous hypertension from dependent positioning and is far less important than maintaining arterial perfusion. Position the leg dependent or flat. Instruct the family explicitly. Override any prior instruction to elevate. Write it in the care plan in capital letters if necessary: DO NOT ELEVATE THIS LEG.[22]
4
Phantom limb pain requires specific preemptive management
Post-amputation phantom limb pain affects 60–80% of patients. It is neuropathic in character — burning, electric, cramping, shooting into the absent limb. It begins at or shortly after amputation. Gabapentin 300 mg TID started preoperatively (or at hospice enrollment if amputation has occurred) is the evidence-based prophylactic approach. Mirror therapy and TENS to the contralateral limb or residual limb may provide additional benefit. Do not dismiss phantom pain as psychological — it is a neurological phenomenon with specific pharmacological treatment. The patient who says their amputated foot hurts is telling the truth.[35]
5
Wound odor — metronidazole gel is a dignity intervention
Gangrenous wound odor is caused primarily by anaerobic bacteria. It is one of the most dignity-impairing symptoms in PAD hospice — patients withdraw from family, refuse visitors, and experience profound shame. Topical metronidazole 0.75% gel applied directly to the wound surface daily is dramatically effective, typically within 3–5 days. Order it at the first visit if there is any wound odor. Activated charcoal dressings as an adjunct. Environmental measures: coffee grounds near the bed, essential oil diffusers, improved ventilation. Address the odor before the patient stops talking about it — once they stop mentioning it, it means they've given up hoping you'll fix it.[34]
6
Teach the family wound care — they are your frontline
In home hospice, families perform the daily wound care between nursing visits. They need specific, written instruction on: dressing change technique (non-adherent primary dressing, metronidazole gel application if ordered, secondary dressing, secure without tape on ischemic skin), what the wound should look like (stable dry gangrene vs. concerning changes), when to call the nurse (new odor, redness spreading from wound edge, fever, increased pain, new drainage), and how to manage wound care emotionally (it is normal to feel distressed — you are not a bad caregiver for finding this difficult). Demonstrate at least two dressing changes before expecting independence.[19]
7
Racial disparities in amputation — know them and address them
Black patients with PAD are amputated at 2–4× the rate of white patients, even after controlling for disease severity, insurance, and comorbidities. This disparity reflects structural inequity in access to vascular specialists and revascularization — not biological predisposition. At hospice enrollment, review whether the patient received equitable vascular evaluation. If a Black patient was offered primary amputation without documented vascular surgery evaluation at a high-volume center, that decision deserves scrutiny. You cannot fix the system at the bedside, but you can ensure the patient in front of you receives equitable assessment and advocacy.[17]
8
Deprescribing at enrollment — stop what doesn't serve comfort
At hospice enrollment, systematically review: statins (no immediate comfort benefit — discontinue), cilostazol (no CLTI benefit — discontinue), ACE inhibitors (reassess — may cause symptomatic hypotension in frail patients; continue if tolerated and serving cardiac comfort), antiplatelets (complex — bleeding risk from ischemic wounds vs. cardiovascular event prevention; individualized discussion), diabetic medications (simplify regimen — A1c targets are irrelevant; prevent symptomatic hyper/hypoglycemia only), and any other medication without a direct comfort indication. Every unnecessary pill is a burden. Reduce the pill count. Keep what manages symptoms.[20]
"The number one thing I tell new nurses before their first PAD visit: look at the bed. If the patient isn't sleeping in it, find out why. Nine times out of ten, it's because the rest pain wakes them up when they're flat. The recliner is the diagnosis. The dangling foot is the self-treatment. And the fact that nobody started around-the-clock opioids before you got there is the clinical failure you're about to fix."
— Waldo, NP
Psychosocial & Spiritual Care
Existential distress, body image devastation, tobacco guilt, amputation grief, and the unique psychosocial terrain of end-stage PAD.
End-stage PAD carries a psychosocial burden that is unique among hospice diagnoses. The wound is visible. The odor is present. The body is visibly disfigured by gangrene or amputation. And for many patients, the knowledge that smoking contributed to this disease adds a layer of guilt that intensifies every other source of suffering. The hospice team that manages only the physical symptoms of PAD and ignores the psychosocial landscape is managing half the disease.[36]
PAD-Specific Psychosocial Challenges
The Visible Wound & Body Image Devastation
Ischemic ulcers and gangrene on the foot or leg are visible, malodorous, and deeply distressing. Patients experience profound shame about the wound and often withdraw from visitors, social activities, and physical intimacy. The odor — when present — compounds the shame to the point of social isolation.
- Address body image explicitly at enrollment: "Many patients feel embarrassed about their wound. That's completely normal. We have specific treatments for the odor and appearance that make a real difference."
- Normalize the wound clinically — this is a medical condition, not a personal failing
- Address odor aggressively with metronidazole gel — odor-related shame is among the most dignity-impairing experiences in end-stage PAD
- Involve social work at enrollment for body image counseling, not at crisis
Tobacco Guilt
A significant proportion of PAD patients smoked, and many know smoking contributed to their disease. They carry guilt silently — often reinforced by family members who say "I told you to quit" or healthcare providers who documented "patient continued to smoke against medical advice."
- Address it directly: "Smoking is an addiction, not a moral failure. The disease that is affecting your legs was accelerated by an addiction, not chosen."
- Say it explicitly and mean it — patients can tell when you're reading from a script
- Redirect family members who express blame — guilt does not serve comfort
- Chaplain referral for patients with deep shame or spiritual distress about their smoking history
Amputation Grief & Functional Identity Loss
- The amputation decision carries profound anticipatory grief: For some patients, amputation represents relief from unbearable pain. For others, it represents loss of identity, mobility, and dignity. Both are valid.
- The patient who chooses amputation for pain relief and the patient who refuses amputation and accepts the gangrenous limb both deserve unconditional clinical support for their decision
- Functional identity loss: For patients who worked physically, walked regularly, or defined themselves through activity, the loss of a limb or ambulation destroys a fundamental aspect of identity. Name it explicitly: "I can see that being unable to walk matters to you beyond just getting around."
- Grief about functional loss is often unaddressed amid the clinical focus on wound management — create space for it
Racial Injustice & No-Revascularization Grief
- Racial injustice and limb loss: Black patients are amputated at rates significantly higher than white patients with similar disease severity. Some patients and families are aware of this disparity and experience their amputation as an act of systemic injustice — not just a medical event. Do not dismiss this. It may be true.[17]
- No-revascularization grief: Being told "there is nothing more we can do for the blood flow" is a devastating moment. The patient hears "we are giving up on your leg." Frame it differently: "We have shifted the focus of your care to managing your pain, protecting your wound, and supporting your quality of life — and we are going to do that aggressively and well."
- Avoid language of surrender. Use language of redirection: "The focus of care has shifted, not ended."
Goals-of-Care Communication in PAD
GOC Framing for PAD Patients
- "What matters most to you right now — is it getting the pain under control, or is there something else that's weighing on you more?"
- "Some patients in your situation are most concerned about pain. Others are most concerned about the appearance of the wound, or about being a burden. What's on your mind?"
- "If the wound were to get worse, what would be most important to you — staying at home, or going to the hospital?"
- Address the amputation question proactively if applicable: "Has anyone talked to you about what might happen if the gangrene progresses? I want to make sure you have the information you need to make the decisions that are right for you."
Spiritual Assessment & Support
- Use the FICA framework: Faith/beliefs, Importance, Community, Address
- "What gives you strength during this time?" opens spiritual conversation without assuming any tradition
- Patients with amputation may experience spiritual crisis: "Why did God let this happen to me?" — chaplain engagement is clinical, not optional
- Legacy work is particularly meaningful for patients facing visible disfigurement — shift focus from the dying body to the enduring person
Suicidal Ideation & Hastened Death Requests
Chronic severe pain, visible disfigurement, functional loss, and social isolation make PAD patients particularly vulnerable to suicidal ideation. Passive wish for death ("I'm ready to go") is common and may be existentially appropriate. Active suicidal ideation with plan requires immediate psychiatric engagement. The patient who requests amputation "to end the pain" may be expressing a desire for death, not a desire for surgery. Assess carefully. Do not avoid the question: "Some patients with this level of pain have thoughts about wanting to die. Have you had thoughts like that?"[36]
"I had a patient — retired machinist, worked with his hands his whole life — and when he lost his leg below the knee, he didn't cry about the pain. He cried because he couldn't stand at his workbench anymore. The identity loss hit harder than the limb loss. If you're only managing the wound and the pain, you're missing the biggest source of suffering in the room. Ask them what they've lost beyond the leg. That's where the real work is."
— Waldo, NP · Terminal2
Family Guide
Plain language for families caring for someone with end-stage PAD. Share, print, or read aloud at the bedside.
Your loved one has a condition where the blood vessels in the legs have become severely narrowed, reducing blood flow to the foot and leg. This causes significant pain — especially at rest and at night — and may have caused wounds or dark changes to the skin that are not healing. The hospice team is here to manage that pain, care for the wound, and support your family through this. You are not expected to do this alone, and the things you may be seeing — the wound, the odor, the pain at night — are all things we have specific treatments for. Please read this guide so you know what to expect and how you can help.
What You May See
- Severe pain in the leg or foot, especially at night and when the leg is raised: This is expected from the blood flow problem. The medications your nurse has prescribed are specifically for this. Do not wait to give them — give them on the schedule, every time. Report pain that is above the goal number your nurse gave you.
- A wound on the foot or leg that may be dark, dry, and black (dry gangrene): This is expected and is being managed conservatively. Watch carefully, but a dry, dark area that is not spreading is not an emergency. Your nurse will assess it at each visit.
- A wound that becomes wet, smelly with a strong odor, or shows redness spreading into the surrounding skin (wet gangrene): Call the nurse the same day. This is an urgent change that needs prompt attention.
- Significant foot or leg odor from the wound: Your nurse has prescribed specific products (metronidazole gel) that reduce this significantly. Follow the dressing protocol exactly — the odor can be controlled much better than it may currently be.
- Swelling of the leg and foot: This is partly from the leg being down. The leg must be kept low (not elevated) to maintain blood flow. This is different from usual swelling instructions — your nurse will explain.
- Dark or mottled changes in the leg: This is expected in advanced disease and reflects the reduced blood flow. Your nurse will assess the skin at each visit.
How You Can Help
- Keep the leg in a low position — do not elevate it on pillows: Gravity helps blood flow to the affected area. Use a recliner or keep the leg flat or slightly below heart level. This is the opposite of standard advice for swelling and is specific to this condition.
- Give pain medications on schedule — do not wait for the patient to ask: Ischemic pain is constant and requires constant medication. A medication given on time is more effective than one given late. Set phone alarms if needed.
- Know the wound dressing protocol exactly: Your nurse will teach you the metronidazole gel application, the non-adherent dressing, and the secondary wrap. Write down the steps. It will become routine within a few days. You are capable of this even if it feels overwhelming at first.
- Know what wet gangrene looks like vs. dry gangrene: Dry = dark, dry, no strong odor, not spreading. Wet = moist, strong foul odor, redness spreading, warmth, possible fever. Dry is being managed. Wet requires a same-day call to the nurse.
- Manage the emotional reality: Watching a gangrenous wound on someone you love is one of the hardest things a family caregiver can experience. It is normal to feel distressed, disgusted, sad, and overwhelmed — sometimes all at once. These feelings do not make you a bad caregiver. Talk to your hospice social worker. You deserve support too.
- Take care of yourself: Caregiver burnout in PAD is high because of the constant wound care demands and the emotional weight of visible disfigurement. Accept help. Sleep when you can. Call the hospice team when you need support — not just when the patient does.
📞 Call the nurse immediately if you see:
New or worsening foul odor from the wound with redness spreading beyond the wound edge (possible wet gangrene / infection). Fever above 101°F (38.3°C) — especially with wound changes. Sudden increase in pain not controlled by the current medication schedule. New dark or mottled areas appearing on the leg or foot. Patient becomes confused, agitated, or unresponsive (possible sepsis). Bleeding from the wound that does not stop with gentle pressure for 10 minutes. Any change in the wound that looks different from what your nurse has described as expected.
🙏 You are part of the care team. Research consistently shows that patients who have engaged, informed family caregivers experience better pain control, less anxiety, and greater dignity at end of life. The wound care you perform between nursing visits, the medications you give on schedule, and the presence you provide at the bedside are not small things — they are the foundation of comfort care. You are doing something that matters profoundly.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside caring for PAD patients. The things you learn after doing this long enough. Not guidelines — real.
- 01Ischemic rest pain requires around-the-clock opioids from the first visit. Not PRN. Not Tylenol with an opioid backup. Not waiting for the patient to ask. If you assess a CLTI patient in a recliner who has not slept in a proper bed for three months because of pain, and you leave that visit without starting around-the-clock morphine or oxycodone — you have not provided adequate care. I don't care what the prior provider had them on. I don't care if the family is nervous about opioids. This is the most undertreated severe pain in hospice, and it is your clinical obligation to fix it today. Start morphine IR 5–10 mg q4h around the clock. Add gabapentin 300 mg TID for the burning neuropathic component. Set a pain goal of 3/10 and titrate until you get there. This patient has suffered enough.
- 02The recliner is your clinical signal. When you walk in and see the patient sleeping in a recliner next to an empty bed, or when the foot is hanging dependent over the side of the mattress, that is a patient managing ischemic rest pain through gravity because no one has given them adequate medication. The dependent position reduces rest pain because gravity assists arterial perfusion to the ischemic foot. The patient figured this out on their own because their pain wasn't being managed. Recognize the recliner as a diagnostic sign — it's as reliable as any lab value — and act on it immediately. Support the dependent position (it's physiologically correct), but supplement it with the medications that should have been started weeks ago.
- 03Do not elevate the ischemic leg. Ever. This is the most common well-intentioned clinical error in PAD wound care. Every nursing school teaches "elevate the legs to reduce edema." In CLTI, elevation reduces arterial perfusion and worsens ischemia. I've seen nurses prop the foot up on three pillows and wonder why the patient is screaming. The dependent position is the correct position. The edema you see is venous — it's a consequence of the leg being down, and it's far less important than maintaining the blood flow that keeps the tissue alive. Override any prior instructions to elevate. Write it in the care plan in capital letters. Tell the family. Tell the aide. Tell everyone who enters that room: this leg stays down.
- 04Dry gangrene and wet gangrene require different urgent responses. Dry gangrene: conservative, protect, monitor. The mummified black toe that is demarcating naturally is not an emergency. Keep it clean, keep it dry, keep it protected, and watch. Wet gangrene: comfort-directed antibiotics now, wound assessment, sepsis protocol if systemic signs present. The difference between dry and wet gangrene is the difference between watchful comfort care and an urgent clinical response. You need to be able to identify which one you're looking at in under ten seconds. Dry is dark, hard, dry, and not spreading. Wet is moist, swollen, red at the edges, foul-smelling, and potentially making the patient septic. Assess the wound character at every visit. The transition from dry to wet is a clinical emergency in the PAD hospice patient.
- 05Metronidazole gel for wound odor is one of the most dignity-restoring interventions in PAD hospice. Order it at the first visit if there is any wound odor. Apply it daily directly to the wound surface under the dressing. The improvement within 3–5 days is dramatic, and patients notice it immediately. I've had patients who hadn't allowed their grandchildren to visit in weeks because of the smell — and after five days of metronidazole gel, the grandkids were back in the room. That's not a medical intervention on paper. That's a life intervention. A patient who has been living with a malodorous wound and cannot bear to have visitors is losing their humanity one day at a time. Fix the odor. Fix it fast. This is as urgent as pain management.
- 06Phantom limb pain is real, it is neurological, and it needs preemptive treatment. Sixty to eighty percent of amputees experience phantom limb pain — burning, electric, cramping sensations in the limb that is no longer there. Start gabapentin before the amputation if possible, or at hospice enrollment if amputation has already occurred. Three hundred milligrams three times daily, titrate up. Do not dismiss it as "psychological" — that's malpractice dressed up as reassurance. The patient who says their amputated foot is on fire is telling you the truth about what their nervous system is doing. Treat it like any other neuropathic pain syndrome. Mirror therapy works for some patients. TENS to the residual limb works for others. But gabapentin is the backbone. Start it early, start it aggressively, and believe the patient when they describe what they feel.
- 07Teach the family the wound care before you need them to do it independently. In home hospice, the family is your wound care team between visits. They will be changing dressings, applying metronidazole gel, and assessing for changes. Do not hand them a written protocol and walk out the door. Demonstrate. Watch them do it. Correct gently. Demonstrate again. Most family caregivers are terrified of the wound initially — it looks awful and they're afraid of hurting their person. After two or three supervised dressing changes, they develop confidence and competence. The investment in teaching pays back every single day. And make sure they know the difference between dry gangrene (watch and wait) and wet gangrene (call now). That one distinction could save a life or prevent unnecessary suffering.
- 08Know that Black patients are amputated at two to four times the rate of white patients, and understand what that means in the room. When a Black patient arrives on your hospice census with a below-knee amputation and you review the chart and see that they were never evaluated by a vascular surgeon for revascularization — that's not a coincidence. That's a system that failed them before you ever met them. You can't fix what happened before enrollment. But you can ensure that every patient on your census, regardless of race, receives the same quality of pain management, wound care, psychosocial support, and clinical advocacy. And if you're in a position to question a premature amputation recommendation for a patient who hasn't been evaluated at a high-volume vascular center — question it. That question might save a limb.
- 09The caregiver burden in PAD hospice is brutal and specific. Unlike many hospice diagnoses where the caregiving is emotional and managerial, PAD caregivers are performing daily wound care on a visible, potentially malodorous wound. They are waking up at night to give medications. They are managing their own emotional reaction to watching gangrene progress on someone they love. They are often doing this alone because the wound has driven away other potential helpers. Screen for caregiver burnout at every visit. The question is simple: "How are YOU doing with all of this?" If they answer "fine" too quickly, they're not fine. Offer respite. Offer social work. Offer the specific permission to say "this is hard" — because it is, and someone needs to acknowledge it.
- 10The patient with end-stage PAD is losing their body one piece at a time — and they're watching it happen. That's different from most hospice diagnoses. The cancer patient can't see their tumor. The heart failure patient can't see their ejection fraction. But the PAD patient looks down and sees a black, gangrenous foot where a healthy foot used to be. They smell the wound. They feel the pain. And they know — sometimes better than we do — exactly what's happening. That awareness requires a different kind of presence from you. Don't look away from the wound. Don't pretend it's not there. Don't use clinical euphemisms that minimize what they can see with their own eyes. Be honest, be direct, and be present. And when they tell you they're scared or disgusted or ashamed — sit down, look them in the eye, and say: "I hear you. And we're going to take care of this together." That sentence, delivered with genuine conviction, is worth more than any medication in your bag.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509-1526.
2
Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329-1340.
3
Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.e40.
4
Prompers L, Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia. 2007;50(1):18-25.
5
Buerger HJ, Beatrous SV, Engel L, et al. Pain management in patients with peripheral arterial disease: a narrative review. Pain Med. 2019;20(Suppl 2):S29-S36.
6
Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890-2909.
7
Faglia E, Clerici G, Caminiti M, et al. Predictive values of transcutaneous oxygen tension for above-the-ankle amputation in diabetic patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2007;33(6):731-736.
8
Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-S67.
9
Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease. Circulation. 2017;135(12):e726-e779.
10
Wagner FW Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle. 1981;2(2):64-122.
11
Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220-234.e2.
12
Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart. 2014;100(5):414-423.
13
Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation. 2006;113(11):e463-e654.
14
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
15
O'Hare AM, Bertenthal D, Shlipak MG, et al. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16(2):514-519.
16
Defined etiologies of arteritis and their clinical manifestations. Vasc Med. 2014;19(5):400-410.
17
Holman KH, Henke PK, Dimick JB, Birkmeyer JD. Racial disparities in the use of revascularization before leg amputation in Medicare patients. J Vasc Surg. 2011;54(2):420-426.
18
Aulivola B, Hile CN, Hamdan AD, et al. Major lower extremity amputation: outcome of a modern series. Arch Surg. 2004;139(4):395-399.
19
Alvarez OM, Kalinski C, Nusbaum J, et al. Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds. J Palliat Med. 2007;10(5):1161-1189.
20
Hartley G, Al-Khaffaf H, Sherwin K. Palliative care in patients with peripheral arterial disease: a narrative review. Ann Vasc Surg. 2019;61:410-417.
21
Goldberg JB, Goodney PP, Cronenwett JL, Baker F. The effect of risk and race on lower extremity amputations among Medicare diabetic patients. J Vasc Surg. 2012;56(6):1663-1668.
22
Abu Dabrh AM, Steain D, Undavalli C, et al. Limb elevation in lower extremity ischemia: a systematic review. Vasc Med. 2015;20(4):345-350.
23
Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. 2013;(2):CD004001.
24
Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6(6):CD003351.
25
Kranke P, Bennett MH, Martyn-St James M, et al. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2015;(6):CD004123.
26
Lee JH. The effects of music on pain: a meta-analysis. J Music Ther. 2016;53(4):430-477.
27
Johnson MI, Paley CA, Jones G, et al. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis. Eur J Pain. 2022;26(3):592-616.
28
Marx W, Ried K, McCarthy AL, et al. Ginger — mechanism of action in chemotherapy-induced nausea and vomiting: a review. Crit Rev Food Sci Nutr. 2017;57(1):141-146.
29
Quain AM, Khardori NM. Nutrition in wound care management: a comprehensive overview. Wounds. 2015;27(12):327-335.
30
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773.
31
Tsai HH, Lin HW, Simon Pickard A, et al. Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review. Int J Clin Pract. 2012;66(11):1056-1078.
32
Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):CD007938.
33
Twycross R, Wilcock A. Palliative Care Formulary (PCF7). 7th ed. Pharmaceutical Press. 2020.
34
Finlay IG, Bowszyc J, Ramlau C, Özvegy J. The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers. J Pain Symptom Manage. 1996;11(3):158-162.
35
Nikolajsen L, Jensen TS. Phantom limb pain. Br J Anaesth. 2001;87(1):107-116.
36
Treat-Jacobson D, McDermott MM, Bronas UG, et al. Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association. Circulation. 2019;139(4):e10-e33.
37
Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events (CHARISMA trial). N Engl J Med. 2006;354(16):1706-1717.
38
Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (HOPE study). Lancet. 2000;355(9200):253-259.
39
Goodney PP, Travis LL, Nallamothu BK, et al. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. 2012;5(1):94-102.
40
Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg. 2006;44(1):108-114.
41
Moxey PW, Hofman D, Hinchliffe RJ, et al. Epidemiological study of lower limb amputation in England between 2003 and 2008. Br J Surg. 2010;97(9):1348-1353.
42
Wukich DK, Raspovic KM. Assessing health-related quality of life in patients with diabetic foot disease: why is it important and how can we improve? Diabetes Care. 2018;41(3):391-397.
43
Siracuse JJ, Schermerhorn ML, Meltzer AJ, et al. Comparison of outcomes after redo-bypass vs amputation in patients with failing infrainguinal bypass. J Vasc Surg. 2014;60(6):1580-1585.
44
Agarwal S, Sud K, Shishehbor MH. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: from 2003–2011. J Am Coll Cardiol. 2016;67(16):1901-1913.
45
Farber A, Eberhardt RT. The current state of critical limb ischemia: a systematic review. JAMA Surg. 2016;151(11):1070-1077.
46
Nehler MR, Duval S, Diao L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60(3):686-695.e2.
47
Reinecke H, Unrath M, Freisinger E, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015;36(15):932-938.
48
Henry AJ, Hevelone ND, Belkin M, Nguyen LL. Socioeconomic and hospital-related predictors of amputation for critical limb ischemia. J Vasc Surg. 2011;53(2):330-339.e1.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.